Drug
LU Af11167
LU Af11167: highest development phase Phase 1, developed by Lundbeck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lu AF11167 NCT02202213 | Phase 1 | Schizophrenia |
Latest
No recent events.
Follow LU Af11167 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.